Novartis/$NVS
1D1W1MYTD1Y5YMAX
Capital at risk
About Novartis
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
- Ticker
- $NVS
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 75,267
- Headquarters
- Basel, Switzerland
- Website
- www.novartis.com
Novartis Metrics
BasicAdvanced
$261B
20.74
$6.61
0.49
$3.08
2.25%
Price and volume
Market cap
$261B
Beta
0.49
52-week high
$170.46
52-week low
$121.57
Average daily volume
2M
Dividend rate
$3.08
Financial strength
Current ratio
0.862
Quick ratio
0.55
Long term debt to equity
93.339
Total debt to equity
116.85
Dividend payout ratio (TTM)
71.08%
Interest coverage (TTM)
13.36%
Profitability
EBITDA (TTM)
23,098
Gross margin (TTM)
74.98%
Net profit margin (TTM)
22.50%
Operating margin (TTM)
32.75%
Effective tax rate (TTM)
17.88%
Revenue per employee (TTM)
$750,000
Management effectiveness
Return on assets (TTM)
10.25%
Return on equity (TTM)
30.35%
Valuation
Price to earnings (TTM)
20.736
Price to revenue (TTM)
4.628
Price to book
5.13
Price to tangible book (TTM)
-7.8
Price to free cash flow (TTM)
17.326
Free cash flow yield (TTM)
5.77%
Free cash flow per share (TTM)
7.917
Dividend yield (TTM)
2.25%
Forward dividend yield
2.25%
Growth
Revenue change (TTM)
2.73%
Earnings per share change (TTM)
-3.43%
3-year revenue growth (CAGR)
8.37%
10-year revenue growth (CAGR)
1.32%
3-year earnings per share growth (CAGR)
22.59%
10-year earnings per share growth (CAGR)
8.97%
3-year dividend per share growth (CAGR)
10.48%
10-year dividend per share growth (CAGR)
5.64%
What the Analysts think about Novartis
Analyst ratings (Buy, Hold, Sell) for Novartis stock.
Analyst projections of the future price of Novartis stock.
Bulls say / Bears say
Novartis beat consensus for Q2 core operating profit and maintained its 2026 outlook, while newer brands including Kisqali, Kesimpta, Scemblix and Pluvicto delivered strong growth that is helping offset legacy-product erosion. (Reuters)
Remibrutinib met the primary goals in two late-stage multiple-sclerosis studies and outperformed a rival on relapse reduction, strengthening a potential growth product whose peak annual sales opportunity has been estimated above $3 billion. (Reuters)
Novartis won a UK High Court ruling rejecting an attempt to invalidate an Entresto patent, preserving an important layer of protection against a planned generic competitor in that market. (Reuters)
Novartis’ late-stage pelacarsen trial failed to reduce major cardiovascular events, undermining a potential blockbuster asset that investors viewed as important to long-term growth. (Reuters)
The Phase III del-desiran study also missed its primary endpoint, increasing pressure on Novartis’ pipeline and raising questions about the strategic payoff from its roughly $12 billion Avidity acquisition. (Reuters)
Generic erosion remains a material earnings headwind: Entresto sales fell 50% year over year in Q2 2026, while Novartis is entering a period of substantial patent expiries. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
Novartis Financial Performance
Revenues and expenses
Novartis Earnings Performance
Company profitability
Upcoming events
No upcoming events
Novartis News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.